Translation Of RNA Nanomedicines From Design To Clinical
Source: Cytiva
Different classes of RNA-based therapeutics include antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA (mRNA). The widespread use of mRNA vaccines for COVID-19 marked 2020 as a breakout year for mRNA technology platforms.
mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.
Translation of RNA Nanomedicines from Design to Clinical presented by Dr. Heinrich Haas, Vice President RNA Formulation & Drug Delivery at BioNTech RNA Pharmaceuticals.
        access the Webinar!
        
            Log In
        
    
    
    
    Get unlimited access to:
            Trend and Thought Leadership Articles
             
        
        
            Case Studies & White Papers
             
        
        
            Extensive Product Database
             
        
        
            Members-Only Premium Content
             
        
    
        Welcome Back! Please Log In to Continue.
        
            X
        
    
    Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
        Subscribe to Cell & Gene
        X
    
    
        Subscribe to Cell & Gene
    
    